NRXP
What one share of NRX Pharmaceuticals holds
Pharmaceutical Preparations
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx”, the “Company”, “we”, “us” or “our”) is a clinical-stage bio-pharmaceutical company which develops and will distribute, through its wholly-owned operating subsidiary, NeuroRx, Inc., (NeuroRx), novel therapeutics for the treatment of central nervous system disorders including suicidal depression, chronic pain, post-traumatic stress disorder (PTSD) and schizophrenia.
NRX Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.11 |
|---|---|
| Profit | −$0.78 |
| Cash and investments | $0.62 |
| Debt | $0.00 |
| Book value | −$0.00 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | — | −$2.86 | — | −$1.81 | — | $18.35 |
| 2019 | — | −$1.10 | — | −$2.85 | — | −$17.03 |
| 2020 | — | −$15.11 | $0.00 | −$0.66 | — | −$10.19 |
| 2021 | — | −$19.84 | $0.00 | −$8.04 | — | $3.54 |
| 2022 | — | −$6.04 | $0.00 | −$6.05 | — | $1.12 |
| 2023 | $0.00 | −$3.98 | $0.00 | −$2.86 | — | −$1.40 |
| 2024 | $0.00 | −$2.36 | $0.00 | −$1.00 | — | −$1.59 |
| 2025 | $0.06 | −$1.34 | — | −$0.66 | — | −$0.50 |